T D Spector

Structure modifying effects of Strontium Ranelate in knee osteoarthritis

OC1 THE ECONOMIC BURDEN OF FRACTURES IN THE EUROPEAN UNION IN 2010 John Kanis, Juliet Compston, Cyrus Cooper, Emma Hernlund, Moa Ivergård, Helena Johansson, Eugene McCloskey, Anders Oden, Judy Stenmark, Axel Svedbom, Bengt Jönsson University of Sheffield, WHO Collaborating Centre, Sheffield, UK, Cambridge University, Department of Medicine, Cambridge, UK, University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, UK, Optum, OptumInsight, Stockholm, Sweden, International Osteoporosis Foundation, IOF, Nyon, Switzerland, Stockholm School of Economics, Department of Economics, Stockholm, Sweden

Strontium Ranelate reduces the number of radiological or radioclinical progressors in patients with primary knee osteoarthritis

P101 PHASE III CLINICAL STUDY OF TRAMADOL HYDROCHLORIDE/ACETAMINOPHEN COMBINATION TABLET IN PATIENTS WITH CHRONIC OSTEOARTHRITIS PAIN OR CHRONIC LOW BACK PAIN – A RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PARALLELGROUP, PLACEBO-CONTROLLED STUDY Takashi Matsushita, Miki Hasebe, Akira Nishimura Teikyo University, School of Medicine, Orthopedic Surgery, Janssen Pharmaceutical K.K., Pain Science, Janssen Pharmaceutical K.K., Site Management, Tokyo, Japan

Эффективность и безопасность стронция ранелата в лечении остеоартроза коленного сустава: результаты двойного слепого рандомизированного плацебоконтролируемого исследования

Objective. Background Strontium ranelate is currently used for osteoporosis. The international, double-blind, randomised, placebo-controlled Strontium ranelate Efficacy in Knee OsteoarthrItis triAl evaluated its effect on radiological progression of knee osteoarthritis. Methods. Patients with knee osteoarthritis (Kellgren and Lawrence grade 2 or 3, and joint space width (JSW) 2.5-5xa0mm) were randomly allocated to strontium ranelate 1 g/day (n=558), 2 g/day (n=566) or placebo (n=559). The primary endpoint was radiographical change in JSW (medial tibiofemoral compartment) over 3 years versus placebo.xa0Secondary endpoints included radiological progression, Western Ontario and McMaster Universities Osteoarthritisxa0Index (WOMAC) score, and knee pain. The trial is registered (ISRCTN41323372). Results. The intention-to-treat population included 1371 patients. Treatment with strontium ranelate was associatedxa0with smaller degradations in JSW than placebo (1 g/day: -0.23 (SD 0.56) mm; 2 g/day: -0.27 (SD 0.63) mm; placebo: -0.37 (SD 0.59) mm); treatment-placebo differences were 0.14 (SE 0.04), 95% CI 0.05 to 0.23, p<0.001 for 1 g/dayxa0and 0.10 (SE 0.04), 95% CI 0.02 to 0.19, p=0.018 for 2 g/day. Fewer radiological progressors were observed with strontium ranelate (p<0.001 and p=0.012 for 1 and 2 g/day). There were greater reductions in total WOMAC scorexa0(p=0.045), pain subscore (p=0.028), physical function subscore (p=0.099) and knee pain (p=0.065) with strontiumxa0ranelate 2 g/day. Strontium ranelate was well tolerated. Conclusions. Treatment with strontium ranelate 1 and 2 g/day is associated with a significant effect on structure inxa0patients with knee osteoarthritis, and a beneficial effect on symptoms for strontium ranelate 2 g/day. Additional supplementary data are published online only. To view these files please visit the journal online (http://dx.doi.xa0org/10.1136/annrheumdis-2012-202231)